Breaking
Drug Watch

AI and New Strategies Combat Rising Antibiotic Resistance

AI and New Strategies Combat Rising Antibiotic Resistance - antibiotic resistance
Developing new antibiotics requires significant investment, with estimates for 2021 ranging from $161 million to $4.54 billion.

Antibiotic resistance is intensifying, creating a situation described as a Red Queen’s Race where both bacteria and humans must constantly adapt just to survive. The death rate from bacteria resistant to treatment has risen by roughly 70 percent annually. This escalation occurs because bacteria prioritize survival and pass these traits to their offspring. Frequent use of drugs like penicillin in clinical, veterinary, and agricultural settings accelerates this resistance.

The financial burden of new treatments

Developing new antibiotics requires significant investment, with estimates for 2021 ranging from $161 million to $4.54 billion. The difficulty lies not only in the cost but in creating a safe, effective medication. A bacterium cannot evolve resistance to a drug it has never encountered. However, the race is difficult; the human species is currently losing this competition.

AI offers a new path forward. Researchers are using artificial intelligence to identify promising peptide sequences that could replace older antibiotics. One lab combines a system similar to a language model with a recommendation algorithm to generate and select these sequences. Biophysics simulations then predict how these molecules interact with bacterial cells or human hosts, allowing researchers to test candidates rapidly.

Protecting hosts instead of killing pathogens

Another approach involves finding drugs that protect patients without necessarily killing the bacteria. Some bacteria release endotoxins that trigger an overreaction in the human immune system, causing damage to the host. Researchers are searching for molecules that neutralize these toxins, thereby stopping the bacteria from killing the patient without forcing the bacteria to develop resistance.

Canada has implemented a wide-ranging strategy to address this crisis, recognizing the problem as a complex web of interlinked issues. The government focuses on basic science, data tracking, and education to ensure antibiotics are used appropriately. Officials emphasize that patients should not use leftover medication, especially for viral infections, as misuse drives the cycle of resistance.

Looking beyond the lab

Antimicrobial resistance is a complicated problem because it’s the old story — it’s survival of the fittest. Bacteria will keep trying to thrive, and so will humans and their animal companions. We need to search for multiple ways forward that allow us to coexist in a changing world.

Rachael (Ré) Mansbach is an associate professor of physics at Concordia University and Tier II Canada Research Chair in Computational Biophysics. Their lab uses computers to understand and develop peptide-based biomaterials for various applications.The views expressed are those of the author(s). Canada Healthwatch publishes a range of perspectives and does not necessarily endorse the opinions presented.

bacteria genetic data healthcare technology
Zenobia Fairweather

Leave a Reply

Your email address will not be published. Required fields are marked *